23 Feb DiscGenics
Flagg Flanagan, Chairman and CEO
Salt Lake City, UT
DiscGenics is a privately held, clinical-stage biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics’s first product candidate, IDCT (rebonuputemcel), is an allogeneic, injectable cell therapy for symptomatic, mild to moderate lumbar disc degeneration. IDCT is a mixture of live Discogenic Cells, which are a unique progenitor cell population derived from donated adult human intervertebral disc tissue, and a viscous carrier. In an FDA-allowed, prospective, randomized, double-blinded, controlled, multicenter clinical study, high dose IDCT produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection. Improvements were sustained at the 52- and 78-week interim readouts with additional data to follow at 104 weeks.